Overview of quinolones in the treatment and prevention of surgical infection

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 4S-7S

  Weigelt, John A ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TROVAFLOXACIN;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIUM CONTAMINATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; GYNECOLOGIC INFECTION; HUMAN; INFECTION PREVENTION; INFECTIOUS COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT INDICATION; WOUND CARE;

EID: 0032458571     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00212-8     Document Type: Article

References (40)

1. Haley RW, Culver DH, White JW, et al. The nationwide nosocomial infection rate: a new need for vital statistics. Am J Epidemiol. 1985;121:159-167.
2. Wenzel RP. Preoperative antibiotic prophylaxis. N Engl J Med. 1992;326:337-339.
3. Nichols RL. Surgical infections: prevention and treatment -1965 to 1995. Am J Surg. 1996;172:68-74.
4. Paradisi F, Corti G. Which prophylactic regimen for which surgical procedure? Am J Surg. 1992;164(suppl 4A):2S-5S.
5. von Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs. 1994:47:872-901.
6. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am. 1995;9:715-730.
7. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384-394.
8. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy. 1993;13(2, pt 2):4S-17S.
9. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg. 1996;223:303-315.
10. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
11. Child J, Andrews J, Boswell F, et al. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother. 1995;35:869-876.
12. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997;39(suppl B):43-49.
13. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994;38: 2471-2476.
14. Aldridge KE, Ashcraft D, Bowman KA. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother. 1997;41:484-487.
15. Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993;37:366-370.
16. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993;37:349-353.
17. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
18. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:487-480.
19. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995;36:385-394.
20. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996;37:955-963.
21. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother. 1997;39(suppl B):75-80.
22. Williams DJ, Hopkins S. Safety and tolerability of intravenous to oral treatment and single dose intravenous or oral prophylaxis with trovafloxacin. Am J Surg. 1998;176(Suppl 6A):74S-79S.
23. Vincent J, Teng R, Dalvie DK, Friedman HL. Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am J Surg. 1998;176(Suppl 6A):8S-13S.
24. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991; 91(suppl 3B):72S-75S.
25. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 1996;100(suppl 6A):3S-12S.
26. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1996;40:2428-2430.
27. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 1997;39(suppl B):87-92.
28. Milsom JW, Smith DL, Corman ML, et al. Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Am J Surg. 1998; 176(Suppl 6A):27S-31S.
29. Bohnen JMA, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti-infective agents for intraabdominal infection. A Surgical Infection Society policy statement. Arch Surg. 1992;127:83-89.
30. Melnik G, Schwesinger WH, Dogolo LC, Teng R, Vincent J. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. Am J Surg. 1998;176(Suppl 6A):14S-17S.
31. Girard AE, Girard D, Gootz TD, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995;39:2210-2216.
32. Onderdonk AB. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis. Infect Dis Clin Pract. 1996;5(3, suppl):S117-S119.
33. Thadepalli H, Reddy U, Chuah SK, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone, in experimental intraabdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 1997;41:583-586.
34. Gorbach SL. Antimicrobial prophylaxis for appendectomy and colorectal surgery. Rev Infect Dis. 1991;13(suppl 10):S815-S820.
35. Donahue PE, Smith DL, Yellin AE, et al. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg. 1998; 176(Suppl 6A):53S-61S.
36. Hemsell DL. Prophylactic antibiotics in gynecologic and obstetric surgery. Rev Infect Dis. 1991;13(suppl 10):S821-S841.
37. Faro S, Phillips LE, Martens MG. Perspectives on the bacteriology of postoperative obstetric-gynecologic infections. Am J Obstet Gynecol. 1988;158:694-700.
38. Maccato ML, Faro S, Martens MG, Hammill HA. Ciprofloxacin versus gentamicin/clindamycin for postpartum endometritis. J Reprod Med. 1991;36:857-861.
39. Roy S, Koltun W, Chatwani A, et al. Treatment of acute gynecologic infections with trovafloxacin. Am J Surg. 1998; 176(Suppl 6A):67S-73S.
40. Roy S, Hemsell D, Gordon S, et al. Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for non-malignant disease. Am J Surg. 1998;176(Suppl 6A):62S-66S.